Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578

SANOFI (SAN)

2467
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

02/22/2013 | 07:58am US/Eastern
Recommend:
0

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
Recommend :
0
React to this article
Latest news on SANOFI
10h ago SANOFI : Genzyme : Announces Winners of Patient Advocacy Leadership (PAL) Awards
13h ago APOLLO HOSPITALS ENTERPRISE : Sanofi to work on diabetes care
16h ago Plant-based vaccines challenge big pharma for $3 billion flu market
1d ago REGENERON PHARMACEUTICALS : Sanofi say sinusitis drug met goals
1d ago GENZYME : Dr. Alan E. Smith, Former Chief Scientific Officer of Genzyme, Joins I..
1d ago GENZYME : The CMTA Links with Genzyme to Discover Therapy for Hereditary Neuropa..
1d ago SANOFI : and Regeneron Announce Positive Phase 2 Top-line Dupilumab Results in P..
1d ago SANOFI : Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Resul..
2d ago GENZYME : Collaborates on Gene Therapy for Rare Disease that Causes Childhood Bl..
4d ago SANOFI : European Pharmaceutical Trade Body EFPIA Affirms Strengthened Commitmen..
Advertisement
Chart
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF